Influence of atorvastatin on fractional and subfractional composition of serum lipoproteins and MMP activity in mice with Triton WR 1339-induced lipaemia

Journal of Pharmacy and Pharmacology

Volumn 63, Issue 6, 2011, Pages 833-839

  Korolenko, Tatyana A ^a   Cherkanova, Marina S ^a   Tuzikov, Fedor V ^b,c   Johnston, Thomas P ^e   Tuzikova, Natalia A ^b,c   Loginova, Viktoriya M ^a   Kaledin, Vassilij I ^d  

^a INSTITUTE OF PHYSIOLOGY   (Russian Federation)

^b BORESKOV INSTITUTE OF CATALYSIS   (Russian Federation)

^c NOVOSIBIRSK STATE UNIVERSITY   (Russian Federation)

^d INSTITUTE OF CYTOLOGY AND GENETICS   (Russian Federation)

^e UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

atorvastatin; lipaemia; lipoprotein fractions and subfractions; matrix metalloproteinases

Indexed keywords

ATORVASTATIN; CHOLESTEROL; GELATINASE A; GELATINASE B; HIGH DENSITY LIPOPROTEIN; INTERMEDIATE DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MATRILYSIN; MATRIX METALLOPROTEINASE; TRIACYLGLYCEROL; TYLOXAPOL; VERY LOW DENSITY LIPOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROGENESIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; DRUG MEGADOSE; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; HYPERLIPIDEMIA; LIPOPROTEIN BLOOD LEVEL; LIVER; MALE; MOUSE; NONHUMAN; PLEIOTROPY; PROTEIN ANALYSIS; TRIACYLGLYCEROL BLOOD LEVEL; X RAY CRYSTALLOGRAPHY;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CHOLESTEROL; HEPTANOIC ACIDS; HYPERLIPIDEMIAS; HYPOLIPIDEMIC AGENTS; LIPOPROTEINS; LIVER; MALE; MATRIX METALLOPROTEINASES; MICE; MICE, INBRED ICR; POLYETHYLENE GLYCOLS; PYRROLES; SCATTERING, SMALL ANGLE; TRIGLYCERIDES; X-RAY DIFFRACTION;

EID: 79956225781     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2011.01287.x     Document Type: Article

References (37)

1. Liao JK, Laufs U,. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005; 45: 89-118. [PubMed: 15822172]. (Pubitemid 40261799)
2. Tentolouris N, et al,. The effect of medications used for the management of dyslipidemia on postprandial lipemia. Curr Medical Chem 2009; 16: 203-217. [PubMed: 19149572].
3. Yoshida M,. Potential role of statins in inflammation and atherosclerosis. J Atheroscler Thromb 2003; 10: 140-144. [PubMed: 14564082].
4. Johnston TP, Palmer WK,. The effect of pravastatin on hepatic 3-hydroxy-3-ethylglutaryl CoA reductase obtained from poloxamer 407-induced hyperlipidemic rats. Pharmacotherapy 1997; 17: 342-347. [PubMed: 9085326]. (Pubitemid 27133360)
5. Johnston TP, et al,. Regression of poloxamer 407-induced atherosclerotic lesions in C57BL/6 mice using atorvastatin. Atherosclerosis 2000; 149: 303-313. [PubMed:10729380]. (Pubitemid 30145540)
6. Johnston TP,. The P-407-induced murine models of dose-controlled hyperlipidemia and atherosclerosis. J Cardivasc Pharmacol 2004; 43: 595-606. [PubMed: 15085072]. (Pubitemid 39090027)
7. Mitsutake R, et al,. Successful intensive lipid-lowering therapy using atorvastatin stabilizes coronary artery plaque as assessed by multi-detector row computed tomography. Intern Med 2007; 46: 859-863. [PubMed: 17575379]. (Pubitemid 47261668)
8. Nishiguchi T, et al,. Synergic action of statins and nitrogen-containing biphosphonates in the development of rhabdomyolysis in L6 rat skeletal fibroblasts. J Pharm Pharmacol 2009; 61: 781-788. [PubMed: 19505369].
9. Shen KP, et al,. Eudogenosedin-A prevents hyperglycaemia, hyperlipidaemia and lipid peroxidation in C57BL/6J mice fed a high-fat diet. J Pharm Pharmacol 2009; 61: 517-525. [PubMed: 19298700].
10. Assmann G, Nofer JR,. Atheroprotective effects of high-density lipoproteins. Annu Rev Med 2003; 54: 321-341. [PubMed: 12414916]. (Pubitemid 37386400)
11. Visser ME, et al,. LDL-C-lowering therapy: current and future therapeutic targets. Curr Cardiol Rep 2008; 10: 512-520. [PubMed: 18950563].
12. Ishikawa M, et al,. Effect of pravastatin and atorvastatin on glucose metabolism in nondiabetic patients with hypercholesterolemia. Intern Med 2006; 45: 51-55. [PubMed: 16484739]. (Pubitemid 43285889)
13. McGinn S, et al,. The effects of high glucose and atorvastatin on endothelial cell matrix production. Diabet Med 2004; 21: 1102-1107. [PubMed: 15384957]. (Pubitemid 39389222)
14. Aprigliano I, et al,. Atorvastatin induces apoptosis by a caspase-9-dependent pathway: an in vitro study on activated rat hepatic stellate cells. Liver Int 2008; 28: 546-557. [PubMed: 18339080]. (Pubitemid 351411142)
15. Millar JS, et al,. Determining hepatic triglyceride production in mice: comparison of poloxamer 407 with Triton WR-1339. J Lipid Res 2005; 46: 2023-2028. [PubMed: 15995182]. (Pubitemid 41248500)
16. Schneider P, et al,. A review of drug-induced lysosomal disorders of the liver in man and laboratory animals. Microsc Res Tech 1997; 36: 253-275. [PubMed: 9140926]. (Pubitemid 27188147)
17. Sierevogel MJ, et al,. Matrix metalloproteinases: a therapeutic target in cardiovascular disease. Curr Pharm Des 2003; 9: 1033-1040. [PubMed: 12678855]. (Pubitemid 36443205)
18. Korolenko TA, et al,. Influence of poloxamer 407 on fractional and subfractional composition of serum lipoproteins of mice. Health 2010; 2: 722-730.
19. Krause BR, Newton RS,. Lipid-lowering activity of atorvastatin and lovastatin in rodent species: triglyceride-lowering in rats correlates with efficacy in LDL animal models. Atherosclerosis 1995; 117: 237-244. [PubMed: 8801869].
20. Nishimoto A, et al,. Lipid-lowering effects of TAK-475, a squalene synthase inhibitor, in animal models of familiar hypercholesterolemia. Eur J Pharmacol 2003; 466: 155-161. [PubMed: 12679152].
21. Otvos JD,. Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy. Clin Lab 2002; 48: 171-180. [PubMed: 11934219]. (Pubitemid 34272531)
22. Tuzikov FV, et al,. General model to describe the structure and dynamic balance between different human serum lipoproteins and its practical application. Med Sci Monit 2002; 8: 79-88. [PubMed: 12070444].
23. Dergunova MA, et al,. Characterization of the novel chemically modified fungal polysaccharides as the macrophage stimulators. Int Immunopharmacol 2009; 9: 729-733. [PubMed: 19268718].
24. Knight CG, et al,. A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases. FEBS Lett 1992; 296: 263-266. [PubMed: 1537400].
25. McTaggart F, Jones P,. Effect of statins on high-density lipoproteins: a potential contribution to cardiovascular benefit. Cardiovasc Drugs Ther 2008; 22: 321-338.
26. Kolovou GD, et al,. The effect of statins on postprandial lipemia. Curr Drug Targets 2007; 8: 551-560. [PubMed: 17570989]. (Pubitemid 46672623)
27. Persson J, et al,. Cytokine response to lipoprotein lipid loading of human monocyte- derived macrophages. Lipids Health Dis 2006; 5: 17-24. [PubMed: 1680087].
28. Katsuda S, Kaji T,. Atherosclerosis and extracellular matrix. J Atheroscler Thromb 2003; 10: 267-274. [PubMed: 14718743].
29. Sundstrom J, Vasan RS,. Circulating biomarkers of extracellular matrix remodeling and risk of atherosclerotic events. Curr Opin Lipidol 2006; 17: 45-53. [PubMed: 16407715]. (Pubitemid 43100302)
30. Roglans N, et al,. High doses of atorvastatin and simvastatin induce key enzymes involved in VLDL production. Lipids 2002; 37: 445-454. [PubMed: 12056585]. (Pubitemid 34535307)
31. Brown RJ, Rader DJ,. Lipases as modulators of atherosclerosis in murine models. Curr Drug Targets 2007; 8: 1307-1319. [PubMed: 18220707].
32. Qiu G, Hill JS,. Atorvastatin decreases lipoprotein lipase and endothelial lipase expression in human THP-1 macrophages. J Lipid Res 2007; 48: 2112-2122. [PubMed: 17644777]. (Pubitemid 47529554)
33. Yasuda T, et al,. Endothelial lipase is increased by inflammation and promotes LDL uptake in macrophages. J Atheroscler Thromb 2007; 14: 192-201. [PubMed:17726294].
34. Conde K, et al,. Hypocholesterolemic actions of atorvastatin are associated with alterations on hepatic cholesterol metabolism and lipoprotein composition in the guinea pig. J Lipid Res 1996; 37: 2372-2382. [PubMed: 8978489]. (Pubitemid 26427451)
35. Ugawa T, et al,. YM-53601, a novel squalene synthase inhibitor, suppresses lipogenic biosynthesis and lipid secretion in rodents. Br J Pharmacol 2003; 139: 140-146. [PubMed: 12746232]. (Pubitemid 36645317)
36. Maurya D, et al,. Microwave induced solubility enhancement of poor water soluble atorvastatin calcium. J Pharm Pharmacol 2010; 62: 1599-1606. [PubMed: 21039544].
37. Mangathayaru K, et al,. Modulatory effect of inula racemosa Hook f. (Asteraceae)on experimental atherosclerosis in guinea pigs. J Pharm Pharmacol 2009; 61: 1111-1118. [PubMed: 19703356].